Ventricular function and natriuretic peptides in sequentially combined models of hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 4, 2010, Pages

  Cavallero, Susana ^a   González, Germán E ^a   Seropian, Ignacio M ^a   Cerrudo, Carolina S ^a   Matorra, Federico ^a   Morales, Celina ^a   Hertig, Cecilia M ^a   Puyó, Ana M ^a   Fernández, Belisario E ^a   Gelpi, Ricardo J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cardiac hypertrophy; Deoxycorticosterone acetate salt hypertension; Natriuretic peptides; Renovascular hypertension

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DEOXYCORTICOSTERONE ACETATE; NATRIURETIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE MODEL; FIBROSING ALVEOLITIS; HEART FUNCTION; HEART LEFT VENTRICLE; HEART VENTRICLE FUNCTION; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOMECHANICS; BLOOD PRESSURE; COLLAGEN; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; HYPERTENSION; HYPERTENSION, RENOVASCULAR; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

EID: 77949741588     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00911.2009     Document Type: Article

References (22)

1. Briest W, Homagk L, Baba HA, Deten A, Rassler B, Tannapfel A, Wagner KF, Wenger RH, Zimmer HG. Cardiac remodeling in erythropoietin-transgenic mice. Cell Physiol Biochem 14: 277-284, 2004.
2. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 10: S143-S148, 1999.
3. Cavallero S, González GE, Puyó AM, Rosón MI, Pérez S, Morales C, Hertig CM, Gelpi RJ, Fernández BE. Atrial natriuretic peptide behaviour and myocyte hypertrophic profile in combined pressure and volumeinduced cardiac hypertrophy. J Hypertens 25: 1940-1950, 2007.
4. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 31: 487-498, 1999.
5. Dávila DF, Donis JH, Odreman R, Gonzalez M, Landaeta A. Patterns of left ventricular hypertrophy in essential hypertension: should echocardiography guide the pharmacological treatment? Int J Cardiol 124: 134-138, 2008.
6. Devereux RB, Roman MJ, Ganau A, de Simone G, Okin PM, Kligfield P. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension 23: 802-809, 1994.
7. Dobrzynski E, Wang C, Chao J, Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36: 995-1001, 2000.
8. 1 receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am J Physiol Heart Circ Physiol 297: H375-H386, 2009.
9. Jennings GL, McMullen JR. Left ventricular hypertrophy: beyond the image and defining the human cardiac phenotype in hypertension. J Hypertens 25: 941-947, 2007.
10. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10: 824-839, 2008.
11. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96: 7403-7408, 1999.
12. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 16: 469-477, 2005.
13. Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, Ogawa H, Kugiyama K, Saito Y, Nakao K, Yasue H. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 86: 1036-1040, 2000.
14. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43: 731-738, 2004.
15. Puyó AM, Scaglione J, Auger S, Cavallero S, Donoso AS, Dupuy HA, Fernández BE. Atrial natriuretic factor as a marker of myocardial compromise in Chagas' disease. Regul Pept 105: 139-142, 2002.
16. Puyó AM, Scaglione J, Auger S, Cavallero S, Postan M, Fernández BE. Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease. Regul Pept 128: 203-210, 2005.
17. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 24: 341-356, 2003.
18. Rysä J, Aro J, Ruskoaho H. Early left ventricular gene expression profile in response to increase in blood pressure. Blood Press 15: 375-383, 2006.
19. Sakata Y, Yamamoto K, Masuyama T, Mano T, Nishikawa N, Kuzuya T, Miwa T, Hori M. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 19: 1905-1912, 2001.
20. Sarda IR, de Bold ML, de Bold AJ. Optimization of atrial natriuretic peptide immunoassay. Clin Biochem 22: 11-15, 1989.
21. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 143: 41-51, 2004.
22. Vittone L, Mundiña-Weilenmann C, Mattiazzi A, Cingolani H. Physiologic and pharmacologic factors that affect myocardial relaxation. J Pharmacol Toxicol Methods 32: 7-18, 1994.